Program outline subject to change. To optimize your viewing experience, please rotate your phone horizontally.

Time Program Outline
  IATDMCT Council Meeting
Time Program Outline
0800-1000 Meeting with Scientific Committee and Regional Section Chairs/Co-Chairs
1000-1500 Pre-Congress Symposium: New Frontiers in Clinical Toxicology
1600-1730 Opening Ceremony Keynote Speaker
1730-1930 Welcome Reception in the Exhibit Hall
1930 Free Evening
 
1000-1500 Pre-Congress Symposium: New Frontiers in Clinical Toxicology
 
1000-1005 Welcome
1005-1050 Leveraging a Wastewater-based Surveillance Network for SARS-CoV-2 to Understand Population Patterns of Substance Use
Michael D. Parkins, University of Calgary, Canada
 
At the end of this session participants will be able to:
  • List the breadth of agents that can be monitored through Wastewater-based surveillance.
  • Explain the role of WBS at a different range of scales across populations.
  • Discuss additional metadata to include with WBS to provide granular surveillance of substance use, and toxicities across populations.
1050-1105 Refreshment Break
1105-1150 Drug Checking Services
Cristiana Stefan, Centre for Addiction and Mental Health, Canada
1150-1230 Lunch
1230-1315 Use of Artificial Intelligence (AI) to Predict and Identify Novel Illicit Drugs
David Wishart, University of Alberta, Canada
1315-1330 Refreshment Break
1330-1415 Public Health and Safety Impacts of Cannabis Legalization in Canada
Shea Wood, Canadian Centre on Substance Use and Addiction, Canada
 
At the end of this session participants will be able to:
  • Describe the key components and objectives of the Cannabis Act in Canada.
  • Identify the impacts of cannabis legalization and various regulations on public health and safety, including observed benefits and potential areas of concern.
  • Summarize remaining knowledge gaps and outline future priorities in cannabis-related policy development, research, prevention strategies, and public education efforts.
This session will provide an overview of the Cannabis Act and Canada’s progress towards its public health and safety objectives. It will address the evolving legal cannabis market and the impacts of legalization and regulations on cannabis use among people in Canada. This will be followed by a discussion on the observed benefits of cannabis legalization in Canada and some areas of concern. Finally, future priorities in policy development, research, prevention, and public education will be addressed.
1415-1500 Semi-synthetic Marijuana Compounds
Christophe Stove, Ghent University, Belgium
Time Program Outline
0715-0815 Breakfast Roundtables
  • R1601: Gut microbiome in individual variability to drug response
  • R1602: The controversy on statin health outcomes: a gap between fundamental science and clinical evidence
  • R1603: How will disposable drug sensors change the TDM landscape?
  • R1604: Challenges of High-Resolution Mass Spectrometry for Drug Testing
  • R1605: TDM of biologics in oncology: is there room for personalized dosing for anti-body drug conjugates
  • R1606: Research integrity in TDM and CT
0830-0930 Plenary Presentation: Promise of Psychedelics
0930-1000 Refreshment Break in the Exhibit Hall
1000-1130 Symposium: Alternative Sampling Strategies Symposium: Anti-Infective Drugs Symposium: TDM of Biologics
1130-1300 Lunch Industry Workshop
1300-1430 Oral Presentations
1430-1600 Refreshment Break & Poster Viewing
1600-1730 Symposium: Pharmacogenetics Symposium: TDM in Oncology Symposium: Young Scientists Symposium
1730-1830 Committee Meetings
1900-2030 Cocktail Reception
 
0715-0815 Breakfast Roundtables
 
R1601: Gut microbiome in individual variability to drug response
Roland Lawson, University of Limoges, France
 
At the end of this session participants will be able to:
  • Explain the bidirectional interaction between drugs and the gut microbiome.
  • Discuss the impact of the gut microbiome in response to immunosuppressants.
  • Discuss potential strategies in the road to precision medicine by targeting the gut microbiome.
The gut microbiome has emerged as a potent drug metabolism ‘organ’, capable of the same type of reactions as the liver or other metabolic organs. The gut microbiome can activate or inactivate drugs, induce toxicity or inefficacy in the host, and influence the pharmacokinetic profile of drugs. The translation of microbiome research into impactful clinical applications for patients requires a robust and structured approach that could help build mechanistic and predictive pharmacokinetic models and develop reliable efficacy and safety models. This session will discuss the contribution of gut microbiome studies to improve TDM of immunosuppressive drugs and explore the gut microbiome as a new frontier in TDM and toxicology.
 
R1602: The controversy on statin health outcomes: a gap between fundamental science and clinical evidence
Hundie Tesfaye, Charles University and Motol University Hospital, Czech Republic
 
At the end of this session participants will be able to:
  • Discuss the current controversy on statin health outcomes.
A generally declared belief is that cholesterol concentrations should be kept low to reduce the risk of cardiovascular diseases. However, studies of the relation between serum cholesterol and all-cause mortality in people on statins treatment have shown contrasting results. Some studies failed to show benefits of too low cholesterol casting doubt on the scientific justification for lowering cholesterol. More importantly, patients on statins present well-defined adverse effects such as myotoxicity including rhabdomyolysis progressing to renal failure.
 
R1603: How will disposable drug sensors change the TDM landscape?
Yasuo Yoshimi, Shibaura Institute of Technology, Japan
 
At the end of this session participants will be able to:
  • Explain the principle of this molecularly imprinted sensor.
  • List the characteristics of this sensor.
  • Discuss how the use of this sensor will change the TDM field.
  • Describe the form of the sensor that is easy to use in the field.
  • Discuss further development strategies.
The research team of the chair is developing disposable sensors that can measure serum concentrations of various high-risk drugs such as vancomycin in a few tens of seconds, which is expected to significantly reduce the time, effort, and cost of analyzing blood levels required for TDM. The chair will discuss with pharmacists and physicians how this sensor will change the flow of TDM and what specifications are needed for the sensor to be widely used.
 
R1604: Challenges of High-Resolution Mass Spectrometry for Drug Testing
Hans H. Maurer, Germany
 
At the end of this session participants will be able to:
  • Explain the possibilities and limitations of HRMS for drug testing.
  • List the challenges should be considered when applying HRMS.
  • Discuss how can these challenges be overcome.
Today, high-resolution mass spectrometry (HRMS) coupled to liquid chromatography (LC), gas chromatography (GC), capillary electrophoresis (CE), or paperspray (PS) is increasingly applied for drug testing etc. It provides universality, high selectivity, specificity, sensitivity, and reproducibility. Nevertheless, some challenges have to be considered such as need of experienced staff, huge amount of data to be handled, integration and automation of several data analysis software packages, regularly updated reference libraries working on all available MS platforms, differentiation of isomers, and finally, harmonization of acceptance criteria for identification.
During the roundtable, these challenges, presented by the chair and contributed by the participants, will be discussed.
References
Maurer HH, Drug Test Anal. 2020, 172.
Maurer HH, Anal Bioanal Chem 2021, 2303.
Strathmann FG et al., Clin Chem 2020, 868.
Wille SM et al., Curr Pharm Des 2022, 1230.

 
R1605: TDM of biologics in oncology: is there room for personalized dosing for anti-body drug conjugates
Dirk Jan Moes, Leiden University Medical Center, Netherlands
 
At the end of this session participants will be able to:
  • Explain the mechanism of action and variability in exposure of ADCs.
  • List the bioanalytical challenges of ADC’s.
  • Discuss strategies to personalize the dose in order to reduce toxicity.
Radix glycyrrhizae has a sweet and flat taste, which can tonify the spleen and Chi, clear heat and detoxify, dispel phlegm and cough, and harmonize various medicines. It is widely used in clinic. The effective ingredients for detoxification include glycyrrhizic acid, glycyrrhetinic acid and so on. The mechanism of detoxification mainly includes regulating P450 enzymes and inducing toxin metabolism, Inducing the expression and function of P-glycoprotein, reacting chemically with toxins, playing an adrenocortical hormone like role. It plays a role in reducing toxicity and increasing efficacy in traditional Chinese medicine formulas.
In traditional Chinese culture, radix glycyrrhizae is indifferent to fame and fortune, adept at adjusting various medicines, and can detoxify hundreds of poisons, earning it the nickname of “National Elder”.

 
R1606: Research integrity in TDM and CT
Teun van Gelder, Leiden University Medical Center, Netherlands
 
 
 
0830-0930 Plenary Presentation: Promise of Psychedelics
Peter Silverstone, University of Alberta, Canada
 
At the end of this session participants will be able to:
  • List potential therapeutic roles for psychedelics.
  • Discuss potential mechanism of actions for psychedelics.
  • Discuss potential risks and toxicology issues for psychedelics.
This session will provide a detailed overview of the potential use of psychedelics as medications both in psychiatry and in other areas, and will provide current neuroscience updates and pathophysiology which have the potential to make these drugs of huge interest in multiple clinical areas.
 
 
 
1000-1130 Symposium: Microsampling
Presented by the Alternative Sampling Strategies Committee
Co-Chairs:
Christophe Stove, Ghent University, Belgium
Suzanne Parker, The University of Queensland, Australia
 
Speakers:
Laura Boffel, Ghent University, Belgium
Sophie Stocker, University of Sydney, Australia
Selected Abstract
Selected Abstract
 
 
 
1000-1130 Symposium: The mysteries of target site concentrations of antibiotics in hard to reach infections: an evolving application of TDM?
Presented by the Anti-Infective Drugs Committee
Co-Chairs:
Dario Cattaneo, L. Sacco University Hospital, Italy
Birgit Koch, Erasmus MC, Netherlands
 
Speakers:
Milo Gatti, University of Bologna, Italy
Birgit Koch, Erasmus MC, Netherlands
Iris Minichmayr, Medical University of Vienna, Austria
Thi Anh Nguyen, University of Sidney, Australia
 
 
 
1000-1130 Symposium: TDM of Biologics
Presented by the TDM of Biologics Committee
Co-Chairs:
Dirk Jan Moes, Leiden University Medical Center, Netherlands
Annick de Vries, Sanquin Diagnostic Services, Netherlands
 
Speakers:
Femke Hooijberg, Amsterdam UMC, Netherlands
Zohra Layegh, Erasmus MC, Netherlands
Panel Discussion
 
 
 
1300-1430 Oral Presentations
 
 
 
1600-1730 Symposium: Genetic diversity in clinical pharmacogenomics: challenges and opportunities for NGS
Presented by the Pharmacogenetics Committee
Co-Chairs:
Erika Cecchin, National Cancer Institute CRO Aviano, Italy
Jesse Swen, Leiden University Medical Centre, Netherlands
 
Speakers:
Preventing severe fluoropyrimidine induced toxicities in the US – the impact of genetic diversity on regulatory agency decisions
Daniel Hertz, University of Michigan, USA
 
The use of NGS in clinical pharmacogenomics in Psychiatry
Daniel Mueller, University of Toronto, Canada
 
Genetic diversity in pharmacogenomics research: the experience from Canada
Rachel Tyndale, University of Toronto, Canada
 
Selected Abstract
 
 
 
1600-1730 Symposium: Innovative ways of Therapeutic Drug Monitoring and Dose optimization in oncology
Presented by the TDM in Oncology Committee
Co-Chairs:
Vikram Gota, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, India
Dirk Jan Moes, Leiden University Medical Centre, Netherlands
 
Speakers:
CarT Cell therapies – quantification and pharmacokinetics
Fenja Klima, Freie Universität Berlin, Germany
 
Quantitative circulation tumor DNA (ctDNA) measurements to guide oncological therapy
Speaker TBA
Selected Abstract
Selected Abstract
 
 
 
1600-1730 Symposium: Young Scientists Symposium Presented by the Young Scientists Committee
Co-Chairs:
Thi Anh Nguyen, University of Sidney, Australia
Lea Wagmann, Saarland University, Germany
 
Speakers:
Point-of-care molecular diagnosis and treatment to tackle global health: tuberculosis as a case study
Gia-Phong Vu, Ho Chi Minh National University, Vietnam
 
Pharmacokinetics of orphan formulations for pediatric patients
Lucas Brstilo, Hospital de Pediatría Garrahan, Argentina
 
How to investigate the toxicokinetics of new psychoactive substances?
Lea Wagmann, Saarland University, Germany
 
Biomarkers of antipsychotic-induced metabolic syndrome: Where we stand and where to head to
Hualin Cai, The Second Xiangya Hospital of Central South University, China
Time Program Outline
0730-0800 Breakfast Roundtables & Committee Meetings
0830-0930 Plenary Presentation
0930-1000 Refreshment Break
1000-1130 Clinical Toxicology & Drugs of Misuse TDM in Oncology Immunosuppressive Drugs & Biomarker
1130-1300 Lunch Industry Workshop
1300-1430 Oral Presentations
1430-1530 IATDMCT Annual General Meeting
1530-1600 Refreshment Break & Poster Viewing
1600-1730 Toxicology & Environmental Health Anti-Infective Drugs TDM of Biologics/ Pharmacometrics
1730-1830 Poster Viewing
1930-2200 Congress Dinner at Mount View Barbecue! A truly unique, western Canadian experience!
Time Program Outline
0830-0930 IATDMCT Award Presentations:
  • C.E. Pippenger Award
  • Victor Armstrong Young Investigator Award
0930-1000 Refreshment Break
1000-1130 Anti-Infective Drugs / Pharmacometrics TDM of Biologics/ TDM in Oncology Regional Asia Pacific Section Symposium
1130-1230 Lunch Industry Workshop
1230-1400 Clinical Toxicology & Drugs of Misuse Workshop Joint Symposium with ACCP Communications Committee Symposium
1400-1530 Closing Ceremony